We understand the challenges emerging biotech companies face in the quest to push the next generation of drugs to market. This is why we have developed our Advance Biotech Grant programs which occur on regular basis in different regions of the world. These programs allow grant recipients receive free products and services.
Apply to our Advance Biotech Grant Program Today!
Your promising molecule requires resources and support to realize its potential. Our Advance Biotech Grant Program, 10th edition, is open for US and Canadian biotech companies, to help you unlock your molecule’s potential.
Two finalists will be awarded $10,000 worth of bioprocessing technologies and/or bioprocessing consultation.
Please submit your completed application before July 1, 2020. The Grand Prize winner will be announced in September 2020.
Excludes BioReliance® Services.
Congratulations Ali Salanti and VAR2 Pharmaceuticals team!
VAR2 Pharmaceuticals is a biotechnology company engaged in the design and development of proprietary therapeutic proteins targeting cancer-specific carbohydrate structures for multiple cancer indications. They have a portfolio of proteins with unique affinity and specificity for these cancer-associated carbohydrates for the development of treatments for cancers where there is no effective therapy, such as sarcoma, triple negative breast cancers and prostate cancer.
Additional congratulations to our semifinalists!
Our Advance Biotech Grant Program, 9th edition, is closed.
Our Advance Biotech Grant Program in Taiwan
We have hosted our 6th edition, for Taiwanese biotech companies, to help accelerate molecules to the clinic faster.Recipients:
Our Advance Biotech Grant Program in China
Apply now for a chance to win free process solution products and services; and/or process development support.Recipients:
Our 2019 Advance Biotech Grant Program for North America
We have hosted our 2019 Advance Biotech Grant Program for North American biotech companies, to help you accelerate to clinic faster.
The three grant recipients are:
Our 2018 Advance Biotech Grant Program for Europe
We have hosted our 2018 Advance Biotech Grant Program, the 5th edition, for European* biotech companies, to help you accelerate to clinic faster.
[*Netherlands, Belgium, Switzerland, United Kingdom, Ireland, France, Germany, Denmark, Finland, Norway, Austria, Spain, Sweden]
Recipients received between €25,000 and €100,000 in technologies and services to accelerate therapeutics to market. View Press Release.
Each grant recipient received 280,000 CNY in technologies and services.
NGM was awarded $89K in products and services. View Announcement.
If you want to be contacted regarding our next Emerging Biotech Grant Program, please leave your details and we will contact you.
Stay the Course
On the journey to commercialization, be sure to stay the course by understanding the global pharmaceutical regulatory landscape.
Unlock your molecule's potential2018 Advance Biotech Grant Program
Bringing your molecule to market. As part of our commitment to meet the needs of the life science community, we’ve developed several programs that recognize stand-out emerging biotech companies. These programs are designed to support biotech start-ups and medium sized companies in solving their current bioprocess development challenges to bring the next generation of molecules to market.
Learn more about the advantages to work with one source on your mAb, linker/ payload supplies and conjugation services.
Review the current dynamics in the RNA therapeutics/vaccines market with a focus on process development and manufacturing strategies.
Learn more on points to consider for successful tech transfers with a focus on cGMP training requirements.
Establishing an open dialog within the biotech community....
A report from the The Economist Intelligence Unit sponsored by Merck.
This paper, which incorporates the results of a survey of 254 pharmaceutical executives from around the world and a range of interviews with industry experts, explores in detail global pharmaceutical companies' growth strategies and their plans for managing the associated risks.